TNFRSF9 and head and neck squamous cell carcinoma: Srivastava et al. showed that the use of CD137 agonists in HNSCC patients promoted the maturation of DC cells induced by cetuximab, and it also enhanced the cross-presentation function of NK cells and DC cells to HNSCC antigens.